Item request has been placed!
×
Item request cannot be made.
×
Processing Request
Reassuring Data for Cardiovascular Health After Switching a Boosted Protease Inhibitor to Dolutegravir.
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
- Author(s): Wood, Brian R1
- Source:
Clinical Infectious Diseases. Oct2023, Vol. 77 Issue 7, p1010-1011. 2p.
- Subject Terms:
- Additional Information
- Abstract:
The article focuses on the relationship between integrase strand transfer inhibitors (INSTIs), particularly dolutegravir (DTG), and cardiovascular health in people with HIV, highlighting the uncertainty surrounding this association. It discusses the findings of a randomized clinical trial (RCT) examining the impact of switching from a boosted protease inhibitor (PI) to DTG on cardiovascular parameters.
No Comments.